VIVUS Inc. (VVUS) is on the upswing today, after the company reported positive results from a late-stage trial of its treatment for erectile dysfunction. Not only does avanifil result in a surprisingly high "magnitude of success in the first 15 minutes," but the treatment was also well-tolerated. The company noted that "there were no drug-related serious adverse events in the study," and added that there were low rates of common side effects, including headache and flushing.

VIVUS is entering a crowded market with its erectile dysfunction drug, with heavyweights such as Viagra and Cialis boasting substantial market share. However, "Knowing that avanafil can be effective within 15 minutes should create an attractive position in the PDE5 market," asserted Charles Bowden, M.D., who serves as senior director of clinical development.

Continue reading Vivus Rallies on Positive Avanifil for Erectile Dysfunction Trial

Vivus Rallies on Positive Avanifil for Erectile Dysfunction Trial originally appeared on BloggingStocks on Mon, 11 Jan 2010 10:20:00 EST. Please see our terms for use of feeds.